Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 14 | 2024 | 360 | 4.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2023 | 105 | 4.250 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2022 | 42 | 3.620 |
Why?
|
| Neoplasms | 9 | 2023 | 882 | 1.950 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 153 | 1.380 |
Why?
|
| Immunotherapy | 9 | 2022 | 171 | 1.030 |
Why?
|
| Melanoma | 2 | 2019 | 140 | 0.990 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 147 | 0.970 |
Why?
|
| Heart Neoplasms | 1 | 2025 | 17 | 0.890 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 14 | 0.840 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2022 | 133 | 0.800 |
Why?
|
| Humans | 38 | 2025 | 29089 | 0.780 |
Why?
|
| Liver Neoplasms | 5 | 2022 | 167 | 0.780 |
Why?
|
| Retrospective Studies | 13 | 2025 | 2651 | 0.760 |
Why?
|
| Myocarditis | 1 | 2022 | 22 | 0.730 |
Why?
|
| Interleukin-6 | 3 | 2023 | 198 | 0.700 |
Why?
|
| Aged | 14 | 2025 | 5627 | 0.640 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 415 | 0.630 |
Why?
|
| Research Design | 1 | 2021 | 188 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 336 | 0.600 |
Why?
|
| Neutropenia | 1 | 2019 | 41 | 0.590 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 67 | 0.590 |
Why?
|
| Azetidines | 1 | 2019 | 6 | 0.590 |
Why?
|
| Exanthema | 1 | 2019 | 14 | 0.580 |
Why?
|
| Piperidines | 1 | 2019 | 48 | 0.560 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2017 | 1 | 0.540 |
Why?
|
| Bone Marrow Diseases | 1 | 2017 | 2 | 0.530 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2017 | 4 | 0.530 |
Why?
|
| Ehrlichiosis | 1 | 2017 | 5 | 0.530 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 9 | 0.520 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 166 | 0.520 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 12 | 0.520 |
Why?
|
| Biological Products | 1 | 2017 | 67 | 0.490 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2022 | 39 | 0.460 |
Why?
|
| Female | 15 | 2025 | 15747 | 0.430 |
Why?
|
| Inflammation | 2 | 2022 | 669 | 0.420 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 2070 | 0.390 |
Why?
|
| Middle Aged | 10 | 2025 | 7458 | 0.390 |
Why?
|
| Male | 14 | 2025 | 14056 | 0.390 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 203 | 0.320 |
Why?
|
| Pneumonia | 2 | 2021 | 89 | 0.320 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 480 | 0.300 |
Why?
|
| Colitis | 2 | 2019 | 54 | 0.290 |
Why?
|
| Treatment Outcome | 8 | 2022 | 2430 | 0.280 |
Why?
|
| Prognosis | 5 | 2022 | 815 | 0.270 |
Why?
|
| Skin | 2 | 2019 | 155 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 137 | 0.230 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2022 | 30 | 0.230 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 62 | 0.220 |
Why?
|
| Adenosine | 1 | 2023 | 33 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 80 | 0.200 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 236 | 0.200 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 94 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 118 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 75 | 0.190 |
Why?
|
| Up-Regulation | 1 | 2023 | 247 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 4 | 0.190 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 6 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 171 | 0.180 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 38 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 413 | 0.180 |
Why?
|
| Adult | 5 | 2021 | 8081 | 0.180 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2021 | 3 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 118 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2021 | 17 | 0.170 |
Why?
|
| Random Allocation | 1 | 2021 | 152 | 0.170 |
Why?
|
| Thyroiditis | 1 | 2020 | 1 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2020 | 288 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 97 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2021 | 80 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2020 | 20 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 251 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 33 | 0.160 |
Why?
|
| Radioimmunotherapy | 1 | 2019 | 1 | 0.160 |
Why?
|
| Bone Marrow | 2 | 2017 | 83 | 0.150 |
Why?
|
| Biopsy | 2 | 2017 | 208 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2019 | 69 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 44 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2021 | 902 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 187 | 0.150 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2019 | 6 | 0.150 |
Why?
|
| United States | 2 | 2022 | 2258 | 0.150 |
Why?
|
| Survival Rate | 1 | 2020 | 433 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 165 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 169 | 0.140 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 149 | 0.130 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2017 | 10 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 28 | 0.130 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 7 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1033 | 0.130 |
Why?
|
| Herpesvirus 1, Human | 1 | 2017 | 24 | 0.130 |
Why?
|
| HIV-1 | 1 | 2017 | 59 | 0.130 |
Why?
|
| Cytokines | 1 | 2019 | 456 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2017 | 271 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 101 | 0.120 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 1 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 21 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 170 | 0.120 |
Why?
|
| Disease Progression | 1 | 2017 | 481 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 787 | 0.120 |
Why?
|
| HIV Infections | 1 | 2017 | 165 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 221 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 556 | 0.090 |
Why?
|
| Mutation | 3 | 2021 | 873 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2022 | 100 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 225 | 0.080 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 59 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 50 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 54 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 11 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2022 | 106 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2021 | 14 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 78 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 122 | 0.040 |
Why?
|
| Patient Safety | 1 | 2021 | 39 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2021 | 74 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 131 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 249 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 148 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 285 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 13 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2022 | 524 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 631 | 0.040 |
Why?
|
| Pregnancy | 1 | 2021 | 1261 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 1286 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1619 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2016 | 11 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 75 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 18 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 2138 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 465 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 379 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2856 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 3239 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 429 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 1483 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 10758 | 0.010 |
Why?
|